Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Core Insights - Cadrenal Therapeutics, Inc. is focused on developing transformative therapeutics to address limitations in current anticoagulation therapy, particularly for rare and high-risk patient populations [1][2] Company Overview - Cadrenal Therapeutics is engaged in the $40 billion anticoagulation market, aiming to bridge critical gaps in acute and chronic anticoagulation management [2] - The company has three clinical-stage assets: - VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with heparin-induced thrombocytopenia (HIT) [4][6] - Tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), currently Phase 3-ready [4][6] - Frunexian, a parenteral small-molecule Factor XIa antagonist for acute hospital settings, currently Phase 2-ready [4][6] Upcoming Events - The management team, including CEO Quang X. Pham, will hold partnering and investor meetings during the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, CA [1][2] Strategic Focus - The company aims to develop novel, differentiated products that address significant gaps in anticoagulation management for specific patient populations [2][4]